Share-Based Compensation (Tables)

6 Months Ended

Jul. 03, 2021

Share-based Payment Arrangement [Abstract]

Schedule of Compensation Expense and Related Income Tax benefit

The compensation expense from the Company’s share-based compensation plans and associated income tax benefit, excluding the effects of excess tax benefits or shortfalls, were included in the Consolidated Statements of Operations as follows (in millions):

	Three Months Ended				Six Months Ended
Compensation costs and related income tax benefit	July 3, 2021		June 27, 2020		July 3, 2021		June 27, 2020
Cost of sales	$	2	$	1	$	4	$	2
Selling and marketing	7		5		13		6
Research and development	8		4		14		6
General and administration	10		7		17		9
Total compensation expense	$	27	$	17	$	48	$	23
Income tax benefit	$	4	$	2	$	7	$	4

Summary of Restricted and Performance Stock-settled Awards

A summary of the Company’s restricted and performance stock-settled awards for the six months ended July 3, 2021 is as follows:

	RSUs			PSUs			RSAs			PSAs
	Units	Weighted-Average Grant Date Fair Value		Units	Weighted-Average Grant Date Fair Value		Shares	Weighted-Average Grant Date Fair Value		Shares	Weighted-Average Grant Date Fair Value
Outstanding at beginning of period	—	$	—	—	$	—	318,565	$	228.08	126,022	$	199.77
Granted	79,057	482.45		38,393	482.42		5,832	483.17		—	—
Released	(101)	482.42		—	—		(147,135)	202.92		(44,023)	151.72
Forfeited	(541)	482.42		(296)	482.42		(5,088)	228.99		(2,102)	237.03
Outstanding at end of period	78,415	$	482.45	38,097	$	482.42	172,174	$	258.20	79,897	$	225.65

Summary of SARs Activity

A summary of the Company’s SARs for the six months ended July 3, 2021 is as follows:

SARs	SARs	Weighted-Average Exercise Price
Outstanding at beginning of period	638,124	$	113.98
Granted	—	—
Exercised	(94,306)	78.73
Forfeited	(3,826)	211.28
Outstanding at end of period	539,992	$	119.46
Exercisable at end of period	446,171	$	97.73

The following table summarizes information related to the SARs outstanding as of July 3, 2021:

	Outstanding		Exercisable
Aggregate intrinsic value (in millions)	$	227	$	197
Weighted-average remaining contractual life	4.0		3.8

Summary of Reflexis Replacement Options Outstanding

A summary of the Reflexis Replacement Options outstanding is as follows:

Reflexis Replacement Options	Options	Weighted-Average Exercise Price
Outstanding at beginning of period	34,424	$	58.09
Granted	—	—
Exercised	(4,706)	58.85
Forfeited	(1,529)	63.01
Outstanding at end of period	28,189	$	57.78
Exercisable at end of period	14,016	$	54.88

The following table summarizes information related to the Reflexis Replacement Options outstanding as of July 3, 2021:

	Outstanding		Exercisable
Aggregate intrinsic value (in millions)	$	14	$	7
Weighted-average remaining contractual life	6.9		6.6